Holen Sie sich die Stockscreener-App
9.17
1.78%
0.16
Handel nachbörslich:
9.03
-0.14
-1.53%
Schlusskurs vom Vortag:
$9.01
Offen:
$9.135
24-Stunden-Volumen:
8,113
Relative Volume:
0.18
Marktkapitalisierung:
$60.34M
Einnahmen:
$43.77M
Nettoeinkommen (Verlust:
$-35.04M
KGV:
-2.8197
EPS:
-3.2521
Netto-Cashflow:
$-5.51M
1W Leistung:
+0.00%
1M Leistung:
+1.55%
6M Leistung:
+12.89%
1J Leistung:
-6.79%
1-Tages-Spanne:
$8.6845
$9.27
1-Wochen-Bereich:
$8.6845
$9.28
52-Wochen-Spanne:
$6.4652
$12.74
Xilio Therapeutics Inc Stock (XLO) Company Profile
Firmenname
Xilio Therapeutics Inc
Sektor
Branche
Telefon
617-833-1027
Adresse
828 WINTER STREET, WALTHAM
Compare XLO vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XLO
Xilio Therapeutics Inc
|
9.17 | 59.55M | 43.77M | -35.04M | -5.51M | -3.2521 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Xilio Therapeutics Inc Stock (XLO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-06 | Eingeleitet | Leerink Partners | Outperform |
| 2022-12-21 | Eingeleitet | Chardan Capital Markets | Buy |
| 2022-01-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-11-16 | Eingeleitet | Cowen | Outperform |
| 2021-11-16 | Eingeleitet | Guggenheim | Buy |
| 2021-11-16 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-11-16 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Xilio Therapeutics Inc Aktie (XLO) Neueste Nachrichten
StemPoint group (XLO) discloses 9.5% Xilio Therapeutics stake via warrants - Stock Titan
Xilio Therapeutics earnings beat by $0.25, revenue topped estimates - Investing.com Canada
Xilio Therapeutics (NASDAQ:XLO) Announces Earnings Results, Beats Estimates By $0.26 EPS - marketbeat.com
Xilio Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Xilio Therapeutics Q2 Results: Sales up 131% YoY to $18.7M - scanx.trade
Xilio Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Xilio Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Form 8K Xilio Therapeutics Inc For: 12 August By Investing.com - Investing.com Nigeria
Xilio Therapeutics reports Q2 2026: $18.7M collaboration revenue, $6.4M net loss, cash $136.0M - TradingView
Xilio Therapeutics (XLO) lifts collaboration revenue and trims net loss in 2026 - Stock Titan
Xilio Therapeutics Reports $18.7 Million Q2 Revenue and FDA Clearance for XTX501 - Quiver Quantitative
Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates - The Manila Times
Xilio Therapeutics Reports Second Quarter 2026 Financial Results And Provides Pipeline And Business Updates - TradingView
Xilio expects to dose cancer patients with XTX501 in H2 2026 - Stock Titan
Xilio Therapeutics (XLO) Holds Steady at $9.18 as Biotech Stock Consolidates Near SupportMomentum Factor - dars.gov.et
Xilio Therapeutics Inc (XLO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Xilio Therapeutics (XLO) Expected to Announce Earnings on Thursday - MarketBeat
XLO Q2'26 Earnings: revenue estimate is 12.72M USD - TradingView
Xilio Therapeutics (NASDAQ:XLO) Trading Down 0.2%Here's Why - MarketBeat
XLO|Xilio Therapeutics Inc|Price:9.110|Chg%:+0.030 - TradingKey
Xilio Therapeutics Inc (XLO) Cash Flow - TradingKey
Xilio Therapeutics Inc (XLO) Balance Sheet - TradingKey
Xilio Therapeutics Inc (XLO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Xilio Therapeutics Inc (XLO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Xilio Therapeutics (XLO) Surges 5%: Key Levels to Watch After Breakout MoveRatio Spread Trade - dars.gov.et
Xilio Therapeutics Inc (XLO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Xilio Therapeutics Inc (XLO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Xilio Therapeutics Inc (XLO) Income Statement - TradingKey
XLO|Xilio Therapeutics Inc|Price:9.132|Chg%:+0.482 - TradingKey
Xilio Therapeutics, Inc. Revenue Breakdown – NASDAQ:XLO - TradingView
Xilio Therapeutics, Inc. (XLO) Stock Price, News, Quote & History - Yahoo! Finance Canada
Price to earnings forward of Xilio Therapeutics, Inc. – NASDAQ:XLO - TradingView
Xilio Therapeutics (XLO) Holds Near Support After Modest DeclineRTH Profile - dars.gov.et
Xilio Therapeutics (XLO) Holds Steady Near Resistance – Biotech Stock in Tight RangeInsider Selling Alerts - dars.gov.et
XLO Stock Price, Quote & Chart - ChartMill
Xilio Therapeutics (XLO) Slides 2% as Biotech Stock Tests Key Support LevelsVolume Rate Change - dars.gov.et
Enterprise value to EBIT forward of Xilio Therapeutics, Inc. – NASDAQ:XLO - TradingView
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Xilio lures three new employees with 107,060 stock options - Stock Titan
Xilio Therapeutics (XLO) Slides as Biotech Sector Headwinds PersistVolume Profile - dars.gov.et
Price to sales forward of Xilio Therapeutics, Inc. – NASDAQ:XLO - TradingView
Xilio Therapeutics, Inc.(NasdaqCM:XLO) added to Russell Microcap Value Benchmark Index - marketscreener.com
Enterprise value to EBITDA forward of Xilio Therapeutics, Inc. – BOATS:XLO - TradingView
Xilio Therapeutics appoints Ben Harshbarger as chief legal officer By Investing.com - Investing.com Nigeria
Xilio Therapeutics, Inc. Announces Appointment of Ben Harshbarger as Chief Legal Officer - marketscreener.com
Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer - citybiz
Xilio Therapeutics appoints Ben Harshbarger as chief legal officer - Investing.com
Xilio Therapeutics taps biotech veteran Ben Harshbarger as legal chief - Stock Titan
XLO Q1 2026 Earnings: Narrower-Than-Expected Loss Fuels Optimism Amid Pipeline ProgressEPS Estimate Trend - dars.gov.et
Xilio Therapeutics, Inc.(NasdaqCM: XLO) added to Russell Microcap Index - marketscreener.com
Enterprise value to revenue forward of Xilio Therapeutics, Inc. – BOATS:XLO - TradingView
Finanzdaten der Xilio Therapeutics Inc-Aktie (XLO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):